Please use this identifier to cite or link to this item: http://ir.swu.ac.th/jspui/handle/123456789/12248
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWudhikarn K.
dc.contributor.authorBunworasate U.
dc.contributor.authorJulamanee J.
dc.contributor.authorLekhakula A.
dc.contributor.authorEkwattanakit S.
dc.contributor.authorKhuhapinant A.
dc.contributor.authorNiparuck P.
dc.contributor.authorChuncharunee S.
dc.contributor.authorNumbenjapon T.
dc.contributor.authorPrayongratana K.
dc.contributor.authorKanitsap N.
dc.contributor.authorWongkhantee S.
dc.contributor.authorMakruasri N.
dc.contributor.authorWong P.
dc.contributor.authorNorasetthada L.
dc.contributor.authorNawarawong W.
dc.contributor.authorSirijerachai C.
dc.contributor.authorChansung K.
dc.contributor.authorSuwanban T.
dc.contributor.authorPraditsuktavorn P.
dc.contributor.authorIntragumtornchai T.
dc.contributor.authoron behalf of Thai Lymphoma Study Group
dc.date.accessioned2021-04-05T03:02:24Z-
dc.date.available2021-04-05T03:02:24Z-
dc.date.issued2019
dc.identifier.issn2780232
dc.identifier.other2-s2.0-85075039642
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85075039642&doi=10.1002%2fhon.2687&partnerID=40&md5=2e82dd1fc922104cdac60ff7696daf52
dc.identifier.urihttp://ir.swu.ac.th/jspui/handle/123456789/12248-
dc.description.abstractEvent free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker for peripheral T cell lymphoma (PTCL). We reviewed 293 systemic PTCL patients at 13 nationwide major university hospitals in Thailand from 2007 to 2014. The median event free survival (EFS) and overall survival (OS) of PTCL patients in our cohort was 16.3 and 27.7 months with corresponding 2-year EFS and 2-year OS of 45.8% and 51.9%, respectively. A total of 118 patients achieved EFS24 (no events during the first 24 mo). Patients who achieved EFS24 had better OS than patients who did not (2-y OS 92% vs 18.8%; HR, 0.1; P <.001). The standardized mortality ratio of patients achieving EFS24 was 18.7 (95% CI, 14.6-22.8). Multivariable analysis demonstrated performance status, histologic subtype, remission status, and EFS24 achievement as independent predictors for OS. Our study affirmed the value of EFS24 as a powerful prognostic factor for PTCL. Further validation in prospective study setting is warranted. ©2019 John Wiley & Sons, Ltd.
dc.subjectcyclophosphamide
dc.subjectcyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus vincristine
dc.subjectdexamethasone
dc.subjectdoxorubicin
dc.subjectlactate dehydrogenase
dc.subjectprednisolone
dc.subjecttumor marker
dc.subjectvincristine
dc.subjectantineoplastic agent
dc.subjectadvanced cancer
dc.subjectaged
dc.subjectArticle
dc.subjectblood toxicity
dc.subjectcancer combination chemotherapy
dc.subjectcancer mortality
dc.subjectcancer prognosis
dc.subjectcancer regression
dc.subjectcancer survival
dc.subjectcontrolled study
dc.subjectdisease severity
dc.subjectdrug dose reduction
dc.subjectevent free survival
dc.subjectfebrile neutropenia
dc.subjectfemale
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoverall survival
dc.subjectperipheral T cell lymphoma
dc.subjectpriority journal
dc.subjectstandardized mortality ratio
dc.subjectsystemic disease
dc.subjectThailand
dc.subjecttherapy delay
dc.subjectadult
dc.subjectdisease free survival
dc.subjecthealth survey
dc.subjectKaplan Meier method
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectperipheral T cell lymphoma
dc.subjectprognosis
dc.subjecttreatment outcome
dc.subjectAdult
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectHumans
dc.subjectKaplan-Meier Estimate
dc.subjectLymphoma, T-Cell, Peripheral
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectProgression-Free Survival
dc.subjectPublic Health Surveillance
dc.subjectThailand
dc.subjectTreatment Outcome
dc.titleEvent free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationHematological Oncology. Vol 37, No.5 (2019), p.578-585
dc.identifier.doi10.1002/hon.2687
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.